The results of clinical trials are crucial for biotechnology companies. Good results can confirm a company’s plans and boost its stock, while bad results can change its direction. These important findings are often shared and discussed at medical conferences throughout the year. These meetings are where companies show off the medicines they’re betting on. Different conferences focus on different things. Some highlight early research or final trials that can lead to approval from regulators. Others give a sense of the industry’s health, where companies and investors meet to network and make deals. Below is a list of key medical meetings and conferences planned for 2026. Top Medical and Industry Meetings in 2026: TBD San Francisco: Every year, biopharma investors and executives meet in San Francisco to discuss deals. Hopefully, a few companies will have new acquisitions or partnerships to announce during the first few days. Feb. 2-3 Miami: A meeting previously called the CEO and Investor Conference and hosted in New York will be held in Miami Beach under a new name in 2026. It will still focus on investors, with networking opportunities for biotechnology CEOs and their backers. March 8-11 Orlando, Florida: Hosted by the Muscular Dystrophy Association, this meeting showcases promising research in neuromuscular disease. It brings together industry leaders, doctors, and scientists to discuss important clinical trial results and real-world data. March 28-30 New Orleans: The growing evidence that GLP-1 medicines can affect various cardiometabolic conditions, and the many clinical trials underway in obesity, makes this meeting likely to feature presentations that guide the field’s direction. April 17-22 San Diego: While the American Society of Clinical Oncology’s meeting is often considered the largest cancer conference, AACR has become an equally important gathering for cancer science, especially early findings on new drug mechanisms or treatment methods. April 18-22 Chicago: AAN often features the latest research on diseases like Alzheimer’s and Parkinson’s, making it one of the top forums for assessing recent progress in neuroscience. May 11-15 Boston: ASGCT has grown with the cell and gene therapy field, becoming a premier conference as the sector expanded and treatments advanced further into human testing. While such therapies still offer much promise, the difficulties companies face in marketing them successfully have made the meeting a health check for the sector. May 27-30 Barcelona, Spain: From hepatitis C to MASH, the burden of liver diseases is large and costly. Europe’s main hepatology meeting is an international forum for the latest research into these disorders as clinicians present data on risk factors and new treatment approaches. May 29-June 2 Chicago: ASCO is a major meeting for cancer drug research with the highest profile and widest impact. The data presented each year often changes treatment standards and can make or break the fortunes of drug developers. June 5-8 New Orleans: ADA is one of the largest medical meetings focused on diabetes and frequently features new research on the care and treatment of different patient populations with the condition. June 11-14 Stockholm: EHA is one of the year’s biggest meetings devoted specifically to hematology and includes results at the forefront of research into leukemias, lymphomas, and non-malignant blood diseases like sickle cell disease. June 22-25 San Diego: BIO’s International Convention is always an important meeting for biotech and pharma companies’ business development teams. It’s also regularly a venue for industry leaders to discuss and debate the top challenges facing the sector. Aug. 28-31 Munich: ESC brings together tens of thousands of cardiology experts to discuss practice-changing research in heart disease. The meeting has been a recent venue for important study results from companies like Alnylam Pharmaceuticals, Novo Nordisk, and AstraZeneca. Sept. 12-15 Seoul, South Korea: WCLC is the world’s top conference on advances in lung cancer, one of the most competitive areas in oncology and a coveted market among drugmakers. Over the last couple of years, the WCLC has been the forum for advances among a closely watched group of cancer immunotherapies called PD-1/VEGF inhibitors, which could change the way many lung tumors are treated. Oct. 23-27 Madrid: ESMO is Europe’s answer to the American Society of Clinical Oncology’s annual meeting and just as often features standard-shifting cancer research. While immunotherapy remains an active area of exploration for drugmakers, increasingly other treatment types like antibody-drug conjugates and radiopharmaceuticals have been featured at oncology conferences. TBD TBD: Thousands of hepatology professionals gather each year at the American Association for the Study of Liver Diseases’ annual meeting. Nov. 7-9 Chicago: AHA is always a major forum for the latest research on medicines to treat diseases of the heart. TBD TBD: Focused on medicines for Alzheimer’s disease, CTAD hosts scientists and experts in the field to discuss new treatment approaches for the neurological condition. TBD TBD: This meeting regularly features compelling new research on treatments for diseases of the blood, from cancers to non-malignant disorders like sickle cell and beta thalassemia.